EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU

Charlotte W M Simons, Loes C H Maton, Maaike van Dartel, Michiel van den Heuvel, Loes den Otter, Carolien Versantvoort, Pieter J Colin iD, Jeroen V Koomen iD

British Journal of Clinical Pharmacology · 2025-05 · 91 (5) · 1500-1510

DOI: 10.1111/bcp.16395 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 22.01.2025. Verfasst von Charlotte W M Simons und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dutch Medicines Evaluation Board, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Drug Approval, Pediatrics. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Health and Digital Executive Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

For new medicines, drug companies obtain regulatory approval on the strategy to generate evidence in the paediatric population, which can be supported by extrapolation of evidence obtained in a reference population. This study investigated whether paediatric marketing authorization applications (PMAAs) supported by extrapolation based on exposure‐matching were more successful—i.e. approval of the targeted paediatric population—and efficient—i.e. duration of the drug development—compared to PMAAs not supported by extrapolation.

Methods

Data was extracted from completed paediatric investigation plans (PIPs), associated drug labels and public assessment reports published on the European Medicines Agency website. Assessment reports were evaluated to assess whether PMAAs were supported by extrapolation based on exposure‐matching. Wilcoxon rank‐sum tests were used to compare PMAAs supported and not supported by extrapolation based on exposure‐matching for outcomes of interest.

Results

Exposure‐matching supported the benefit/risk assessment of 39.6% of the PMAAs. Targeted and approved minimum age of the paediatric population were comparable for PMAAs where extrapolation based on exposure‐matching supported the benefit/risk assessment (2.0 vs . 2.0 years, P ‐value = .72), but not for PMAAs not supported by extrapolation (0.2 years vs . 0.5 years, P ‐value = .05). Completion of drug development was 5.4 years vs . 4.3 years ( P = .04) in PMAAs supported by extrapolation based on exposure‐matching compared to those not supported by extrapolation, respectively.

Conclusions

PMAAs supported by extrapolation based on exposure‐matching succeeded more often in obtaining marketing approval in the targeted paediatric population than PMAAs not supported by exposure‐matching, but were also less efficient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalPediatricsHumansChildEuropean UnionRisk AssessmentDrug DevelopmentMarketingDrug Industry

Stichwörter der Autor:innen

drug developmentextrapolationpaediatric medicinepharmacometricsregulatory science

Autor:innen und Institutionen

  • Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
  • Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Cognitive Neuropsychiatry and Clinical Neuroscience, Mental Health and Neuroscience Research Institute (MHeNs), Maastricht University, Maastricht, the Netherlands.

ORCID-Profile: Pieter J Colin, Jeroen V Koomen

Förderung

  • European Health and Digital Executive Agency

Zitieren

APA

Simons, C. W. M., Maton, L. C. H., van Dartel, M., van den Heuvel, M., den Otter, L., Versantvoort, C., Colin, P. J., & Koomen, J. V. (2025). A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU. British Journal of Clinical Pharmacology, 91(5), 1500-1510. https://doi.org/10.1111/bcp.16395

Vancouver

Simons CWM, Maton LCH, van Dartel M, van den Heuvel M, den Otter L, Versantvoort C, et al. A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU. British Journal of Clinical Pharmacology. 2025;91(5):1500-1510. doi:10.1111/bcp.16395

BibTeX
@article{Simons2025,
  author = {Simons, Charlotte W M and Maton, Loes C H and van Dartel, Maaike and van den Heuvel, Michiel and den Otter, Loes and Versantvoort, Carolien and Colin, Pieter J and Koomen, Jeroen V},
  title = {A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {5},
  pages = {1500--1510},
  doi = {10.1111/bcp.16395}
}
Kostenlos starten →